Lake Street Capital Lowers ReWalk Robotics (NASDAQ:LFWD) Price Target to $4.50

ReWalk Robotics (NASDAQ:LFWD) had its price objective lowered by equities researchers at Lake Street Capital from $6.00 to $4.50 in a note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Lake Street Capital’s target price indicates a potential upside of 154.96% from the stock’s current price.

Several other research analysts have also recently issued reports on the company. Laidlaw started coverage on ReWalk Robotics in a research report on Monday, February 10th. They issued a “buy” rating and a $10.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $13.00 price objective on shares of ReWalk Robotics in a research note on Thursday.

ReWalk Robotics Price Performance

NASDAQ LFWD opened at $1.77 on Thursday. The stock has a market capitalization of $18.76 million, a price-to-earnings ratio of -0.71 and a beta of 2.05. ReWalk Robotics has a 1-year low of $1.25 and a 1-year high of $7.70. The business’s fifty day moving average price is $1.74 and its 200-day moving average price is $2.41.

Insider Buying and Selling

In related news, major shareholder Global Fund Lp Lind II sold 381,676 shares of the stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $3.36, for a total value of $1,282,431.36. Following the completion of the sale, the insider now directly owns 1,049,430 shares of the company’s stock, valued at approximately $3,526,084.80. This represents a 26.67 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Michael Swinford bought 21,622 shares of the firm’s stock in a transaction on Monday, November 25th. The shares were purchased at an average price of $2.03 per share, for a total transaction of $43,892.66. Following the purchase, the director now owns 65,040 shares in the company, valued at $132,031.20. This trade represents a 49.80 % increase in their position. The disclosure for this purchase can be found here. 2.50% of the stock is owned by insiders.

About ReWalk Robotics

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.